Routledge a Taylor & Francis Group
|Number of Pages
In light of recent clinical breakthroughs in the field, this lucid book presents up-to-date and comprehensive discussions of current and potential applications of monoclonal antibody-based agents as frontline and adjuvant treatments in cancer-highlighting the impact of these therapies in areas such as improved response rates and safety profiles while providing an informed understanding of their present limitations.
Stimulates exchanges between clinicians and basic scientists working towards the next generation of monoclonal antibody-based agents!
Written by a panel of researchers at the cutting edge of therapeutic antibody development, Monoclonal Antibody-Based Therapy of Cancer
elucidates the basic, preclinical principles underlying antibody-based therapies
examines pivotal results obtained from ongoing clinical trials in malignancies, such as lymphoma and leukemia
focuses on a novel monoclonal antibody treatment for non-Hodgkin's lymphoma recently approved by the Food and Drug Administration
describes state-of-the-art advances in the management of breast cancer, melanoma, and other solid tumors
Together with references to key sources in the literature, tables, drawings, and photographs, this useful resource furnishes excellent direction for medical and radiation oncologists, immunologists, nuclear medicine specialists, hematologists, pharmacologists, biochemists, and graduate and medical school students in these disciplines.